REG I|[alpha]| is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer

A Sekikawa; H Fukui; X Zhang; T Maruo; T Tsumura; Y Okabe; T Wakasa; Y Osaki; T Chiba; T Tomita; T Oshima; J Watari; H Miwa

首页> 外文期刊>British Journal of Cancer >REG I|[alpha]| is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer

【24h】

REG I|[alpha]| is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer

机译：REG I |α|是预测不可切除的IV期胃癌患者对S-1加顺铂化疗反应的生物标志物

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background:The regenerating gene Iα (REG Iα) is involved in gastric carcinogenesis as an antiapoptotic factor. Therefore, we investigated whether REG Iα confers resistance to chemotherapeutic drugs in gastric cancer (GC) cells and whether REG Iα expression is useful for predicting the response to chemotherapy and outcome in patients with GC.

机译：背景：再生基因Iα（REGIα）作为抗凋亡因子参与胃癌的发生。因此，我们调查了REGIα是否赋予胃癌（GC）细胞化疗药物耐药性，以及REGIα表达是否可用于预测GC患者对化疗的反应和结局。

著录项

来源
《British Journal of Cancer 》 |2013年第2期| 共7页
作者
A Sekikawa; H Fukui; X Zhang; T Maruo; T Tsumura; Y Okabe; T Wakasa; Y Osaki; T Chiba; T Tomita; T Oshima; J Watari; H Miwa;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy [J] . Y Mitani, N Oue, S Matsumura, Oncogene . 2007 ,第30期

机译：Reg IV是胃癌患者的血清生物标志物，可预测对基于5-氟尿嘧啶的化学疗法的反应
2. Treatment of stage IV gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients [J] . Masaaki Saito, Hirokazu Kiyozaki, Osamu Takata, World Journal of Surgical Oncology . 2014 ,第1期

机译：在某些患者中采用S-1和顺铂诱导化疗治疗IV期胃癌，然后进行根治性切除
3. Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer. [J] . Byung Woog Kang, Jong Gwang Kim, Yee Soo Chae, Investigational new drugs. . 2012 ,第4期

机译：II-1期IV期（M0）胃癌患者辅以S-1和顺铂3周联合辅助化疗的初步研究。
4. A Successfully Treated Case of Stage IV Gastric Cancer with Outlet Stenosis Undergoing Curative Gastrectomy After Preoperative S-1 Plus Cisplatin Following Laparoscopic Assisted Gastrectomy. [C] . Y.Okumura, Y.Iwasaki, M.Ohashi, International Gastric Cancer Congress . 2009

机译：腹腔镜辅助胃切除术后，在术前S-1加顺铂术后成功处理了阶段IV胃癌的阶段胃癌。
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. REG Iα is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer [O] . A Sekikawa, H Fukui, X Zhang, 2013

机译：REGIα是预测无法切除的IV期胃癌患者对S-1加顺铂化疗反应的生物标志物
7. Treatment of stage IV gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients [O] . Masaaki Saito, Hirokazu Kiyozaki, Osamu Takata, 2015

机译：在某些患者中采用S-1和顺铂诱导化疗治疗IV期胃癌，然后进行根治性切除

REG I|[alpha]| is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer

摘要

著录项

相似文献

相关主题

期刊订阅